News

The next major catalyst is the FDA’s July 23-24 advisory committee meeting, where regulators will consider whether seven peptides should be added to the Section 503A Bulks List.

Hims & Hers Health trades at $33.39 per share and has stayed right on track with the overall market, gaining 9.6% over the last six months. At the same time, the S&P 500 has returned 11.4%.

A cash-secured put on Hims & Hers stock is one way to potentially buy the stock for a discount or achieve a healthy return.

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $35.15, moving +2.24% from the previous trading session.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

An FDA advisory committee will review seven peptides for possible inclusion on the Section 503A Bulks List on July 23-24.

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $36.17, moving 5.51% from the previous trading session.

Hims & Hers Health has delivered a very large 3 year return, yet the stock still screens as undervalued on market multiples while only scoring weakly on broader valuation checks. A roughly 344.6% return over 3 years puts Hims & Hers Health among the stronger performers in digital health, which raises the bar for what future growth and execution need to justify. Recent traction in branded GLP-1 and peptide related offerings can support optimistic revenue expectations, but evolving FDA...

One prioritizes rapid consumer growth and profitability; the other commands scale but faces concentration risk.

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

CEO Andrew Dudum said Hims treats 10,000 to 15,000 patients daily and aims to become the healthcare industry’s “gold standard.”

Peptides are short-chain amino acids that are formulated into drugs. Insulin is a peptide. Legions of other peptides are on the market in the “wellness” industry, promoted for everything from athletic performance to skin care, mental focus, and “romantic connection”—the latter pitched by a startup called Feel Peptides.

The uncommitted facility provides Hims with a working-capital tool as it scales its healthcare and pharmacy operations.

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and t

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

The FDA staff’s view clashes with RFK Jr.’s push to deregulate peptides and move more of them toward Category 1 status.

In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $33.39, indicating a -1.62% shift from the previous trading day.

OMCL vs. HIMS: Which Stock Is the Better Value Option?

Hims had 2.6 million subscribers in Q1, up 9% year over year, with Q2 expected to show how much the Novo deal is helping demand.

We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the best weight loss drugs on this list. TheFly reported on June 17 that Barclays maintained its Overweight rating on HIMS while increasing its price target to $39.00 from $29.00. The […]

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $32.96, moving 1.73% from the previous trading session.

Hims & Hers Health (NYSE:HIMS) is expanding its GLP-1 weight-loss treatment offerings, adding new options to its telehealth platform. The company has entered into a partnership with Novo Nordisk to provide access to medications such as Wegovy and Ozempic. Hims & Hers Health is extending its international reach through the acquisition of Eucalyptus. Hims & Hers Health, best known for its direct-to-consumer telehealth services, is moving deeper into prescription weight management at a time...

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.

Dudum also expressed interest in Garmin integration, saying company teams are actively exploring the feature.

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.

Barclays raises its target to $39 as GLP-1 momentum builds and a peptide ruling approaches

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $31.89, moving +1.33% from the previous trading session.